Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer

Journal of the National Cancer Institute

Volumn 105, Issue 18, 2013, Pages 1385-1393

  Ajona, Daniel ^a   Pajares, María J ^a,b   Corrales, Leticia ^a   Perez Gracia, Jose L ^c   Agorreta, Jackeline ^a,b   Lozano, Maria D ^c   Torre, Wenceslao ^c   Massion, Pierre P ^d   De Torres, Juan P ^c   Jantus Lewintre, Eloisa ^f   Camps, Carlos ^e,f   Zulueta, Javier J ^c   Montuenga, Luis M ^a,b   Pio, Ruben ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF VALENCIA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; BRONCHUS MUCOSA; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG LAVAGE; LUNG TUMOR; MAJOR CLINICAL STUDY; PERFORMANCE; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT DISEASE;

ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; COMPLEMENT ACTIVATION; COMPLEMENT C4B; COMPLEMENT PATHWAY, CLASSICAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886897241     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt205     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1): 11-30.
2. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5): 395-409.
3. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012;5(8): 992-1006.
4. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med. 2005;353(12): 1288-1290.
5. Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol. 2011;6(10): 1763-1773.
6. Kay AB, Smith AF, McGavin CR, Tuft SB. Immunoglobulins and complement in pleural effusions associated with bronchogenic carcinoma. J Clin Pathol. 1976;29(10): 887-889.
7. Gminski J, Mykala-Ciesla J, Machalski M, Drozdz M, Najda J. Immunoglobulins and complement components levels in patients with lung cancer. Rom J Intern Med. 1992;30(1): 39-44.
8. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol. 1998;113(2): 173-182.
9. Ajona D, Castano Z, Garayoa M, et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 2004;64(17): 6310-6318.
10. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9): 785-797.
11. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol. 2007;178(9): 5991-5998.
12. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol. 2008;45(1): 169-179.
13. Okroj M, Corrales L, Stokowska A, Pio R, Blom AM. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother. 2009;58(11): 1771-1780.
14. Corrales L, Ajona D, Rafail S, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;189(9): 4674-4683.
15. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
16. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111(6): 1710-1717.
17. Pio R, Garcia J, Corrales L, et al. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(10): 2665-2672.
18. Jantus-Lewintre E, Sanmartin E, Sirera R, et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011;74(2): 326-331.
19. Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006;66(4): 2116-2128.
20. Roos A, Nauta AJ, Broers D, et al. Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol. 2001;167(12): 7052-7059.
21. Kojouharova M, Reid K, Gadjeva M. New insights into the molecular mechanisms of classical complement activation. Mol Immunol. 2010;47(13): 2154-2160.
22. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012;81(7): 628-639.
23. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res. 2010;8(11): 1453-1465.
24. Ghai R, Waters P, Roumenina LT, et al. C1q and its growing family. Immunobiology. 2007;212(4-5): 253-266.
25. Paidassi H, Tacnet-Delorme P, Garlatti V, et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol. 2008;180(4): 2329-2338.
26. Varsano S, Frolkis I, Ophir D. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am J Respir Crit Care Med. 1995;152(3): 1087-1093.
27. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9(11): 1225-1235.
28. Nunez-Cruz S, Gimotty PA, Guerra MW, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012;14(11): 994-1004.
29. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116(1): 271-284.
30. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9): 3713-3718.